What is Petra Pharma?
Petra Pharma is a clinical-stage biopharmaceutical enterprise dedicated to the inhibition of phosphoinositide (PI) signaling pathways. These pathways are fundamental to cellular processes such as growth, division, and trafficking, which are frequently dysregulated in cancer and other serious pathologies. Founded in 2016, the company leverages deep scientific expertise to develop targeted therapies that address significant unmet medical needs. By focusing on the molecular mechanisms that drive disease progression, Petra Pharma aims to transform the standard of care for patients facing complex oncological challenges, establishing a strong competitive moat through its proprietary research and development platform.
How much funding has Petra Pharma raised?
Petra Pharma has raised a total of $48M across 1 funding round:
Series A
$48M
Series A (2016): $48M with participation from ARCH Venture Partners, Harris & Harris Group, Inc., Eli Lilly and Company, Johnson & Johnson Innovation - JJDC, Inc, The Partnership Fund for New York City, Alexandria Venture Investments, WuXi AppTec, and AbbVie Inc.
Key Investors in Petra Pharma
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Eli Lilly and Company
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines, with a strong focus on oncology and immunology.
Johnson & Johnson Innovation - JJDC, Inc
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies, providing innovative medicines and surgical products used in areas such as oncology and neuroscience.
What's next for Petra Pharma?
With the support of this recent capital injection, Petra Pharma is well-positioned to accelerate its clinical development programs. The strategic focus will likely remain on advancing its lead candidates through the regulatory pipeline while expanding its research capabilities in PI signaling inhibition. As the company matures, the integration of its scientific findings into broader therapeutic applications will be critical for long-term value creation. The involvement of major pharmaceutical partners suggests a potential for future collaborative development or licensing agreements, which would further validate the company's technology and provide the necessary infrastructure to scale its operations globally. Investors will be closely monitoring the firm's progress in upcoming clinical trials as it seeks to demonstrate the efficacy and safety of its novel therapeutic interventions.
See full Petra Pharma company page
